Novel stent technologies to address and overcome clinical shortcomings
Qvanteq AG
Incorporated
12.01.2009Headquarters
ZürichSupport
Qvanteq develops novel stent technologies to address and overcome the clinically adverse effects of today’s available coronary artery stents. A coronary stent is a small (metal) mesh tube which is being implanted into coronary arteries to prevent heart attacks.
Qvanteq is ISO 13485 certified. It is a spin-off company from the Swiss Federal Institute of Technology (ETH) Zurich. The company was awarded with the CTI start-up label in 2012. Qvanteq was founded in early 2009 and is held by private investors. Its Headquarter is located at the Technopark in Zurich, Switzerland.
News
Die venture leaders China stehen fest (startupticker.ch)
Red Herring announces European winners (startupticker.ch)
IMD announces Start-up Competition Winners (startupticker.ch)
Swiss coronary stent company Qvanteq enrolled first patient in clinical study (startupticker.ch)
Qvanteq closes series B financing round of CHF4 million (startupticker.ch)
Eight promising start-ups present at the next Swiss Venture Day (startupticker.ch)
CTI Start-up Label for Numab, Qvanteq, SwissTV and Virometix (startupticker.ch)
Milestones news
Qvanteq obtains venture kick first round 10 KCHF
